145 related articles for article (PubMed ID: 35098660)
21. Programmed Cell Death-One Inhibition Therapy in Classical Hodgkin Lymphoma.
Al-Hadidi SA; Chuang HH; Miranda RN; Lee HJ
Clin Lymphoma Myeloma Leuk; 2021 Feb; 21(2):e105-e111. PubMed ID: 33160934
[TBL] [Abstract][Full Text] [Related]
22. Analysis and Investigation of Bioinformatics and Epigenetics Reveal the Underlying Mechanisms by which FLOT2 Modulates the Progression of Diffuse Large B-cell Lymphoma.
Zhang Y; Chen Y; Guo Q; Zhang Y; Liu A
Discov Med; 2024 Mar; 36(182):621-631. PubMed ID: 38531803
[TBL] [Abstract][Full Text] [Related]
23. Expression pattern of PD-L1 and PD-L2 in classical Hodgkin lymphoma, primary mediastinal large B-cell lymphoma, and gray zone lymphoma.
Tanaka Y; Maeshima AM; Nomoto J; Makita S; Fukuhara S; Munakata W; Maruyama D; Tobinai K; Kobayashi Y
Eur J Haematol; 2018 May; 100(5):511-517. PubMed ID: 29377256
[TBL] [Abstract][Full Text] [Related]
24. Lower PTEN may be associated with CD8+ T cell exhaustion in diffuse large B-cell lymphoma.
Zheng S; Ma J; Li J; Pang X; Ma M; Ma Z; Cui W
Hum Immunol; 2023 Oct; 84(10):551-560. PubMed ID: 37481380
[TBL] [Abstract][Full Text] [Related]
25. Higher Peripheral Blood IFN-γ-/IL-4+ Th2 Lymphocytes Are Associated with Lower Rate of Relapse in Patients with Lymphoma.
Dehghani M; Ramzi M; Kalani M; Golmoghaddam H; Arandi N
Immunol Invest; 2022 Feb; 51(2):452-463. PubMed ID: 33148063
[TBL] [Abstract][Full Text] [Related]
26. Genetic signature of CTLA-4, BTLA, TIM-3 and LAG-3 molecular expression in colorectal cancer patients: Implications in diagnosis and survival outcomes.
Kamal AM; Wasfey EF; Elghamry WR; Sabry OM; Elghobary HA; Radwan SM
Clin Biochem; 2021 Oct; 96():13-18. PubMed ID: 34217699
[TBL] [Abstract][Full Text] [Related]
27. Fascin expression in diffuse large B-cell lymphoma, anaplastic large cell lymphoma, and classical Hodgkin lymphoma.
Bakshi NA; Finn WG; Schnitzer B; Valdez R; Ross CW
Arch Pathol Lab Med; 2007 May; 131(5):742-7. PubMed ID: 17488159
[TBL] [Abstract][Full Text] [Related]
28. Grey zone lymphoma with features intermediate between diffuse large B-cell lymphoma and classical Hodgkin lymphoma: a clinicopathological study of 14 Epstein-Barr virus-positive cases.
Elsayed AA; Satou A; Eladl AE; Kato S; Nakamura S; Asano N
Histopathology; 2017 Mar; 70(4):579-594. PubMed ID: 27735994
[TBL] [Abstract][Full Text] [Related]
29. Epigenetic abnormalities of classical Hodgkin lymphoma and its effect on immune escape.
Liu Y; Huang R; Liu L; Meng Y; Liu X
Cell Biochem Funct; 2020 Apr; 38(3):242-248. PubMed ID: 31709594
[TBL] [Abstract][Full Text] [Related]
30. Different aberrant expression pattern of immune checkpoint receptors in patients with PTCL and NK/T-CL.
Liao Z; Lv X; Liu S; He Z; Chen S; Wang L; Li W; Li Y
Asia Pac J Clin Oncol; 2018 Oct; 14(5):e252-e258. PubMed ID: 29368793
[TBL] [Abstract][Full Text] [Related]
31. Prognostic and clinicopathological significance of PD-1/PD-L1 expression in the tumor microenvironment and neoplastic cells for lymphoma.
Xie M; Huang X; Ye X; Qian W
Int Immunopharmacol; 2019 Dec; 77():105999. PubMed ID: 31704289
[TBL] [Abstract][Full Text] [Related]
32. The immune checkpoint molecules PD-1, PD-L1, TIM-3 and LAG-3 in diffuse large B-cell lymphoma.
Chen BJ; Dashnamoorthy R; Galera P; Makarenko V; Chang H; Ghosh S; Evens AM
Oncotarget; 2019 Mar; 10(21):2030-2040. PubMed ID: 31007846
[TBL] [Abstract][Full Text] [Related]
33. Expression level of immune checkpoint inhibitory factors in preeclampsia.
Madadi S; Mohammadinejad S; Alizadegan A; Hojjat-Farsangi M; Dolati S; Samadi Kafil H; Jadidi-Niaragh F; Soltani-Zangbar MS; Motavalli R; Etemadi J; Eghbal-Fard S; Aghebati-Maleki L; Danaii S; Taghavi S; Yousefi M
Hum Immunol; 2022; 83(8-9):628-636. PubMed ID: 35906120
[TBL] [Abstract][Full Text] [Related]
34. Deregulated Expression of Immune Checkpoints on Circulating CD4 T Cells May Complicate Clinical Outcome and Response to Treatment with Checkpoint Inhibitors in Multiple Myeloma Patients.
Kulikowska de Nałęcz A; Ciszak L; Usnarska-Zubkiewicz L; Frydecka I; Pawlak E; Szmyrka M; Kosmaczewska A
Int J Mol Sci; 2021 Aug; 22(17):. PubMed ID: 34502204
[TBL] [Abstract][Full Text] [Related]
35. Elevated frequencies of CD8 T cells expressing PD-1, CTLA-4 and Tim-3 within tumour from perineural squamous cell carcinoma patients.
Linedale R; Schmidt C; King BT; Ganko AG; Simpson F; Panizza BJ; Leggatt GR
PLoS One; 2017; 12(4):e0175755. PubMed ID: 28423034
[TBL] [Abstract][Full Text] [Related]
36. Diagnostic utility of programmed cell death ligand 1 (clone SP142) immunohistochemistry for malignant lymphoma and lymphoproliferative disorders: A brief review.
Sakakibara A; Kohno K; Ishikawa E; Suzuki Y; Tsuyuki Y; Shimada S; Shimada K; Satou A; Takahara T; Ohashi A; Takahashi E; Kato S; Nakamura S; Asano N
J Clin Exp Hematop; 2021 Dec; 61(4):182-191. PubMed ID: 34511582
[TBL] [Abstract][Full Text] [Related]
37. Evaluation of the diagnostic and prognostic value of PDL1 expression in Hodgkin and B-cell lymphomas.
Menter T; Bodmer-Haecki A; Dirnhofer S; Tzankov A
Hum Pathol; 2016 Aug; 54():17-24. PubMed ID: 27045512
[TBL] [Abstract][Full Text] [Related]
38. BTLA marks a less cytotoxic T-cell subset in diffuse large B-cell lymphoma with high expression of checkpoints.
Quan L; Lan X; Meng Y; Guo X; Guo Y; Zhao L; Chen X; Liu A
Exp Hematol; 2018 Apr; 60():47-56.e1. PubMed ID: 29353075
[TBL] [Abstract][Full Text] [Related]
39. Pembrolizumab in the treatment of refractory primary mediastinal large B-cell lymphoma: safety and efficacy.
Camus V; Bigenwald C; Ribrag V; Lazarovici J; Jardin F; Sarkozy C
Expert Rev Anticancer Ther; 2021 Sep; 21(9):941-956. PubMed ID: 34233557
[No Abstract] [Full Text] [Related]
40. PD-1 expression on the surface of peripheral blood CD4
Zhang W; Bai JF; Zuo MX; Cao XX; Chen M; Zhang Y; Han X; Zhong DR; Zhou DB
Cancer Med; 2016 Nov; 5(11):3077-3084. PubMed ID: 27709793
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
